The present invention relates to combination therapy with a mutant IDH inhibitor of Formula (I) and a Bcl-2 inhibitor, for the treatment of cancer.

##STR00001##

The present invention provides a compound that has an inhibitory effect on DYRK and that is represented by general formula (I):

##STR00001##

wherein Q, R.sup.1, R.sup.2 and R.sup.3 are as defined in the description.

The present invention provides a compound that has an inhibitory effect on DYRK and that is represented by general formula (I):

##STR00001##

wherein Q, R.sup.1, R.sup.2 and R.sup.3 are as defined in the description.

Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Provided herein are compositions comprising panthenol-citrate containing materials. In particular, panthenol citrate compounds, oligomers, and polymers, and methods of use and synthesis thereof, are provided herein. Panthenol-citrate containing materials are a class of nontoxic, photoluminescent-chromophore-containing compounds, oligomers, and polymers with high absorption in the UVA and UVB range that can be incorporated and/or engineered into a variety of optically-active biomaterials (e.g., sunscreen products).

Provided herein are compositions comprising panthenol-citrate containing materials. In particular, panthenol citrate compounds, oligomers, and polymers, and methods of use and synthesis thereof, are provided herein. Panthenol-citrate containing materials are a class of nontoxic, photoluminescent-chromophore-containing compounds, oligomers, and polymers with high absorption in the UVA and UVB range that can be incorporated and/or engineered into a variety of optically-active biomaterials (e.g., sunscreen products).

The present invention relates to biomolecule conjugates which comprise a biomolecule wherein at least one non-natural amino acid (NNAA) is integral to the structure of the biomolecule and wherein the NNAA is a point of attachment of a linker to which a payload, particularly a cytotoxic agent, is attached. More specifically, this invention relates to conjugates of cell-binding agents and active release products comprising cytotoxic agents wherein the conjugates are produced by means of a cycloaddition reaction. Methods of production, pharmaceutical compositions and methods of use are provided.

The present invention relates to biomolecule conjugates which comprise a biomolecule wherein at least one non-natural amino acid (NNAA) is integral to the structure of the biomolecule and wherein the NNAA is a point of attachment of a linker to which a payload, particularly a cytotoxic agent, is attached. More specifically, this invention relates to conjugates of cell-binding agents and active release products comprising cytotoxic agents wherein the conjugates are produced by means of a cycloaddition reaction. Methods of production, pharmaceutical compositions and methods of use are provided.

The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

##STR00001##